Status: Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
Participants needed: 1,000
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: PfizerUpdated: Jun 30, 2026Locations: 341
Eligibility criteria
Male participants aged ≥18 years (or the minimum age of consent in accordance wi... [+4]
Any medical or psychiatric condition including recent (within the past year) or... [+9]